Diffuse large B-cell lymphoma (DLBC) is a subtype of lymphoma with the worst prognosis. Existing treatment methods are not effective enough due to its high occurrence of metastasis. Therefore, identification of effective therapeutic targets is becoming increasingly important. In this research, lncRNA Dopamine β hydroxylase antisense RNA 1 (DBH-AS1) was found to be upregulated in DLBC tissues and cells. Knockdown of DBH-AS1 suppressed the proliferation, migration and invasion of cancer cells. Afterwards, RBP BUD13 homolog (BUD13) was found to be upregulated in cancer tissues and cells while binding to DBH-AS1. Fibronectin 1 (FN1) was the downstream mRNA of BUD13. FN1 was upregulated in DLBC and was positively correlated with DBH-AS1. Further rescue assays proved that DBH-AS1 mediated FN1 expression by recruiting BUD13. In the meantime, BUD13 stabilized FN1 mRNA to promote FN1 expression. In this way DBH-AS1/BUD13/FN1 axis was confirmed. A set of rescue assays proved that DBH-AS1 regulated DLBC progression via BUD13 and FN1. The function and mechanism of DBH-AS1 was investigated for the first time in DLBC. DBH-AS1 might become a therapeutic target in lymphoma treatment in the future. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.